Strides Pharma Science growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+6.4%+12.7%+9.8%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+15.3%+8.0%+72.8%
+18.4%+16.8%+179.6%
−84.0%+3,914.4%+55.6%
−84.5%+5,132.7%+65.5%
+14.5%+3.6%−12.0%
+21.8%+24.8%−4.7%
+2.7%−2.4%+1,478.6%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

STAR₹1,001.10

Strides Pharma Science Ltd.

· Pharma & Health
₹ CrorePeersSPARCSUPRIYASHILPAMEDTHYROCARERUBICONVIYASHYATHARTHPARKHOSPSMcap ₹9,227 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—+9.8+12.7+6.4—
EBITDA Growth—+72.8+8.0+15.3—
EBIT Growth—+179.6+16.8+18.4—
Net Income Growth—+55.6+3,914.4-84.0—
EPS Growth—+65.5+5,132.7-84.5—
Total Assets Growth—-12.0+3.6+14.5—
Total Equity Growth—-4.7+24.8+21.8—
Cash from Operations Growth—+1,478.6-2.4+2.7—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.